By: IPP Bureau
Last updated : February 17, 2022 5:52 pm
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Pebble Global Holdings, a privately held Texas-based leader in non-psychotropic cannabinoid research for drug development, announced that a sponsored research program entitled “Evaluation of Multi-Cannabinoid Formulations in Ovarian Cancer” was initiated in 2020 and presently exists between Pebble and MD Anderson Cancer Center.
MD Anderson is one of the world's most respected centers devoted exclusively to cancer patient care, education, prevention, research and ranked No. 1 in cancer in the U.S. News & World Report’s 2021-2022 annual “Best Hospitals.”
Despite being one of the most researched, ovarian cancer is the leading cause of gynecological cancer in the US and second most globally. It is the fifth leading cause of cancer death in US women, with 22,000 diagnosed in 2021, resulting in 14,000 deaths. 75% of patients are “advanced” at initial diagnosis, with 1 in 6 dying within 90 days and treatment limited by severe adverse effects from the current standard of care.
“Our team has thoroughly enjoyed working with MD Anderson the past two years on this novel therapy. We’re excited to continue with MD Anderson, to improve cancer treatment standard of care. Pebble’s non-THC, non-psychotropic approach permits a regulatory drug pathway that allows both domestic and global distribution, so we can help as many suffering women as possible,” says Pebble Founder & CEO - Patrick Moran.